NASDAQ: ELABElevai Labs Inc Stock
$0.66-0.01 (-1.49%)
Updated Apr 26, 2024
ELAB Price
$0.66
Fair Value Price
N/A
Market Cap
$11.42M
52 Week Low
$0.57
52 Week High
$4.24
P/E
-1.65x
P/B
2.98x
P/S
11.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.71M
Earnings
-$4.30M
Gross Margin
66.2%
Operating Margin
-250.03%
Profit Margin
-251.2%
Debt to Equity
0.36
Operating Cash Flow
-$5M
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELAB Overview
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELAB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELAB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELAB is good value based on its book value relative to its share price (2.98x), compared to the US Biotechnology industry average (5.85x)
P/B vs Industry Valuation
ELAB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ELAB due diligence checks available for Premium users.
Be the first to know about important ELAB news, forecast changes, insider trades & much more!
ELAB News
Valuation
ELAB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.65x
Industry
14.88x
Market
41.14x
ELAB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.98x
Industry
5.85x
ELAB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELAB's financial health
Profit margin
Revenue
$698.6k
Net Income
-$1.2M
Profit Margin
-165.9%
ELAB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ELAB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.2M
Liabilities
$1.4M
Debt to equity
0.36
ELAB's short-term assets ($4.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELAB's short-term assets ($4.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELAB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.2B
Investing
$11.2M
Financing
-$1.5B
ELAB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELAB vs Biotech Stocks
Elevai Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.